Status:
COMPLETED
Exisulind Versus Placebo After Surgical Removal of the Prostate
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
OSI Pharmaceuticals
Conditions:
Prostatic Neoplasms
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
This is a study in which patients with prostate cancer treated by surgical removal of the prostate and considered to be at risk for prostate cancer recurrence will receive Exisulind 250 mg twice a day...
Eligibility Criteria
Inclusion
- Males 18 years of age or older with prostate cancer treated primarily by radical prostatectomy and randomized within 45 days after surgery may be eligible for enrollment into this protocol. Participants cannot have had hormonal therapy, cryotherapy, thermotherapy, or radiotherapy prior to entering the study.
Exclusion
Key Trial Info
Start Date :
February 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2008
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT00166426
Start Date
February 1 2003
End Date
May 1 2008
Last Update
November 16 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905